



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/EP2014/061478

(22) International Filing Date:

3 June 2014 (03.06.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

13170447.0	4 June 2013 (04.06.2013)	EP
13173939.3	27 June 2013 (27.06.2013)	EP
14166450.8	29 April 2014 (29.04.2014)	EP

(71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors: VAN GOOL, Michiel, Luc, Maria; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). ALONSO-DE DIEGO, Sergio-Alvar; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). CID-NÚÑEZ, José, Maria; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). DELGADO-GONZÁLEZ, Óscar; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). DECORTE, Annelies, Marie, Antonius; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). MACDONALD, Gregor, James; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). MEGENS, Antonius, Adrianus, Hendrikus,


Petrus; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). TRABANCO-SUÁREZ, Andrés, Avelino; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). GARCÍA-MOLINA, Aránzazu; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES). ANDRÉS-GIL, José, Ignacio; c/o Janssen-Cilag, S.A., Calle Jarama, 75, Poligono Industrial, E-45007 Toledo (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS



(57) Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives of Formula (I) as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 ("mGluR2"). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved, especially CNS disorders.



Declarations under Rule 4.17:

Published:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))* — *with international search report (Art. 21(3))*